Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial

Madhi, Shabir A; Kwatra, Gaurav; Richardson, Simone I; Koen, Anthonet L; Baillie, Vicky; Cutland, Clare L; Fairlie, Lee; Padayachee, Sherman D; Dheda, Keertan; Barnabas, Shaun L; +27 more... Bhorat, Qasim Ebrahim; Briner, Carmen; Ahmed, Khatija; Aley, Parvinder K; Bhikha, Sutika; Bhorat, AE; Esmail, Aliasgar; Horne, Elizea; Kaldine, Haajira; Mukendi, Christian K; Madzorera, Vimbai Sharon; Manamela, Nelia P; Masilela, Mduduzi; Hermanus, S Tandile; Motlou, Thopisang; Mzindle, Nonkululeko; Oelofse, Suzette; Patel, Faeezah; Rhead, Sarah; Rossouw, Lindie; Taoushanis, Carol; van Eck, Samuel; Lambe, Teresa; Gilbert, Sarah C; Pollard, Andrew J; Moore, Penny L; Izu, Alane; (2023) Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. The Lancet Infectious diseases, 23 (3). pp. 295-306. ISSN 1473-3099 DOI: https://doi.org/10.1016/S1473-3099(22)00596-5

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1473-3099(22)00596-5

Abstract

Share

Download

Filename: Madhi_etal_2022_Durability-of-chadox1-ncov-19.pdf

Licence: Creative Commons: Attribution 4.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar